Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Myeloma: early-phase trial registry
167 of 441 indexed Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11 of 28,963 conditions by registered trial count.
441 US clinical trials · 167 currently recruiting · #11 of 28,963 conditions by registered trial count
Multiple Myeloma: 441 US clinical trials tracked, 167 recruiting.
Multiple Myeloma is the subject of 441 registered US clinical trials on ClinicalTrials.gov, 167 of them currently open to new participants. 52 are in Phase 3-4 (later-stage) and 298 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Open enrollment, early-phase tilt
Multiple Myeloma has 441 registered US clinical trials, 167 of them open to new participants right now, about 38% of the total.
- 167
- recruiting participants now
- 38%
- of trials open to enrollment
- 52
- in Phase 3-4 (later-stage)
- 34
- top sponsor: Memorial Sloan Kettering Cancer Center
Corpus placement: #11 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Myeloma recruits in line with its size-band peers.
167 of 441 indexed trials (37.9%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Myeloma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 441 trials (7.7%). 154 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Myeloma enrolment sits around 65 participants.
Median target enrolment is 65 among the 439 trials that report a genuine target (sentinel values excluded). 262 of those (59.7%) plan for fewer than 100 participants.
-
Multiple Myeloma research is mostly interventional.
386 interventional and 55 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
441 total, page 4 of 9
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Mayo Clinic
NCT06145581
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Starton Therapeutics
NCT06087653
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
Yale University
NCT05002816
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital
NCT05909059
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
NCT06083922
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Robert Flavell, MD, PhD
NCT05892393
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Joshua Sasine, MD, PhD
NCT05887167
Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma
Stanford University
NCT06461988
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Washington University School of Medicine
NCT07200102
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
City of Hope Medical Center
NCT06572605
TriPRIL CAR T Cells in Multiple Myeloma
Marcela V. Maus, M.D.,Ph.D.
NCT05020444
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
NCT07105059
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
Hackensack Meridian Health
NCT03909412
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
NCT06066346
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Washington University School of Medicine
NCT06623630
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
City of Hope Medical Center
NCT06048250
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06398457
Agriculture Health Study
National Cancer Institute (NCI)
NCT00352924
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Alliance for Clinical Trials in Oncology
NCT00048958
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Bristol-Myers Squibb
NCT01838512
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
SWOG Cancer Research Network
NCT04071457
MMRF Molecular Profiling Protocol
Multiple Myeloma Research Foundation
NCT02884102
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Celgene
NCT04975997
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Pfizer
NCT05317416
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
Stichting European Myeloma Network
NCT05257083
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Janssen Research & Development
NCT04923893
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Paul Richardson, MD
NCT01208662
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Dana-Farber Cancer Institute
NCT01177527
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
University of Alabama at Birmingham
NCT04000880
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT05083169
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline
NCT04246047
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene
NCT02773030
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
NCT03989414
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Janssen Research & Development
NCT04181827
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development
NCT03652064
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma
University of Arkansas
NCT00734877
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Celgene
NCT03651128
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
NCT04162210
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
NCT05024045
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
University of Miami
NCT04268498
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
NCT00602641
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline
NCT04484623
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Memorial Sloan Kettering Cancer Center
NCT04459416
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development
NCT04108195
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
AbbVie
NCT03539744
PRospective Multiple Myeloma Impact Study
SkylineDx
NCT02911571
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
University of Chicago
NCT03729804
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Washington University School of Medicine
NCT02253316
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT04586426
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
C4 Therapeutics
NCT04756726
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 142 |
| Phase 3 | 45 |
| Phase 4 | 7 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Multiple Myeloma right now
167 recruiting of 441 indexed (38% open).
Phase mix: 52 late (III/IV) vs 298 early (I/II) (early-phase heavy).
Top sponsor: Memorial Sloan Kettering Cancer Center (34 trials), 9 others listed. 50 shown below, recruiting first. #11 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Multiple Myeloma?
PlainTrial tracks 441 US clinical trials for Multiple Myeloma, of which 167 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Multiple Myeloma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.